AstraZeneca to present new cancer drug data at ESMO 2016

AstraZeneca has announced plans to present data on a number of new cancer therapies at this year's annual congress of the European Society for Medical Oncology (ESMO).

A total of 46 scientific presentations will be given by AstraZeneca and its global biologics research and development arm MedImmune at ESMO 2016, which will be held in Copenhagen from October 7th to 11th.

These will include the sharing of first-line data demonstrating the superiority of Faslodex to a standard-of-care aromatase inhibitor medicine in postmenopausal women with HR-positive locally-advanced or metastatic breast cancer who have not been previously treated with any hormonal medicine.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "Faslodex is an important treatment option for women with breast cancer. The FALCON trial illustrates how an approved medicine can further improve outcomes in patients with metastatic breast cancer."

The company will also present updated safety and efficacy data from the Study 1108 durvalumab monotherapy cohort in non-small cell lung cancer and head and neck squamous cell carcinoma (HNSCC), plus a comparative analysis of PD-L1 diagnostic assays in 500 HNSCC tumour samples.

Oncology is one of AstraZeneca's most important focus areas, with six new medicines in this field expected to be launched between 2014 and 2020.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.